Achillion Reports Positive Interim Results From Odalasvir Study - Quick Facts

(RTTNews) - Achillion Pharmaceuticals, Inc. (ACHN) announced additional interim results from a Phase 2 study evaluating odalasvir, also known as ACH-3102, a NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for either six or eight weeks of treatment in patients with treatment-naïve genotype 1 chronic hepatitis C virus infection. The primary objective of the study was determination of sustained viral response 12 weeks, or SVR12, after the completion of therapy. The company said, of the patients treated for six weeks in this cross-over cohort, 100 percent remained HCV RNA undetectable twelve weeks after completing therapy.

The company said Odalasvir and sofosbuvir were well tolerated in the Phase 2, open-label, randomized, partial-crossover study with no significant adverse events, ECG findings, or lab abnormalities observed during treatment.

In May 2015, Achillion announced it had granted Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, an exclusive, worldwide license to develop and, upon regulatory approval, commercialize HCV products and regimens containing one or more of Achillion's HCV assets which include odalasvir, ACH-3422, and sovaprevir.